Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

dapagliflozin

27 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of dapagliflozin

89 trials tracked of dapagliflozin: 69 in phase 3 or 4 and 30 with published results. The most-cited published study has 647 citations.

89Trials tracked

69Phase 3 & 4

0Recruiting

30With published results

Phase distribution

Phase 4 23 Phase 3 46 Phase 2 13 Phase 1 4 Other / NA 3

Phase 3 Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Completed · 647 cited
Phase 4 Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure Completed · 431 cited
Phase 3 Add-on to Thiazolidinedione (TZD) Failures Completed · 404 cited
Phase 3 Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Completed · 394 cited
Phase 3 A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes Completed · 362 cited
Phase 3 An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets Completed · 315 cited

Show 44 more trials

Phase 3 Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack. Completed · 275 cited
Phase 4 Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus Completed · 248 cited
Phase 4 An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin Completed · 192 cited
Phase 3 Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed · 151 cited
Phase 3 Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed · 86 cited
Phase 3 Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years Completed · 84 cited
Phase 3 Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes Completed · 78 cited
Phase 3 Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes Completed · 78 cited
Phase 4 Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea Completed · 73 cited
Phase 3 Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes Completed · 69 cited
Phase 4 Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles. Completed · 59 cited
Phase 3 A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838) Completed · 56 cited
Phase 3 DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction Completed · 55 cited
Phase 3 DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction Completed · 54 cited
Phase 4 Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2 Completed · 45 cited
Phase 3 Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old Completed · 35 cited
Phase 3 SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2 Completed · 35 cited
Phase 3 Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure Completed · 28 cited
Phase 3 Phase III Insulin Add-On Asia Regional Program - ST Completed · 28 cited
Phase 4 Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D) Completed · 15 cited
Phase 3 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. Completed · 14 cited
Phase 3 A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone Completed · 13 cited
Phase 4 Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria Completed · 10 cited
Phase 3 A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease Completed · 6 cited
Phase 4 Vildagliptin Versus Dapagliflozin on Glucagon Completed
Phase 4 Foxiga Korea Local Phase 4 Study Completed
Phase 4 A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients Completed
Phase 4 Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2) Completed
Phase 4 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed
Phase 4 Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension Completed
Phase 4 Dapagliflozin Effects on Epicardial Fat Completed
Phase 4 Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes Completed
Phase 4 Dapagliflozin at Discharge on Hospital Heart Failure Readmission Completed
Phase 4 Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects Completed
Phase 4 Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM Completed
Phase 4 Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration Completed
Phase 4 Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation Completed
Phase 4 Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients Completed
Phase 4 Anti-Diabetic Medications to Fight PD and LBD Completed
Phase 3 A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise Completed
Phase 3 A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone Completed
Phase 3 Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Completed
Phase 3 A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes Completed
Phase 3 Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin Completed

Showing the 50 most-cited and recently-updated of 89 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

‹ Prev 1 2 3 Next ›